AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Spero Therapeutics, Inc.
Video analysis: SPRO
All videosNo video analysis for this stock yet. Request one from our team.
News: SPRO
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that the Compensation Committee of Spero's Board of Directors approved a grant, made on September 1, 2026, of an aggregate of 102,000 restricted stock unit awards (RSUs) and 67,600 stock options to new employees under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).
Spero Therapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference
CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that Esther Rajavelu, President and Chief Executive Officer, will present at the H.C.
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics, Inc. (SPRO) Q2 2026 Earnings Call Transcript
Spero Therapeutics Q2 Earnings Call Highlights
Spero Therapeutics NASDAQ: SPRO used its second-quarter update to outline a strategic shift toward immune-mediated diseases, supported by the FDA approval of Utebzi and a new licensing agreement for SP001, an antibody candidate the company plans to develop initially for IgG4-related disease.
Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update
CAMBRIDGE, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that on July 22, 2026, the Compensation Committee of Spero's Board of Directors approved a grant, to be made on August 3rd, of an aggregate of 324,622 stock options and 162,311 restricted stock unit awards (RSUs) to a new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan).
Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced that announced that it will report its financial results for the second quarter ended June 30, 2026 on Wednesday, August 12, 2026, after market close.
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero's clinical leadership team as the Company advances SP001, a Phase 2-ready third-generation anti-CD40L antibody for IgG4-related disease (IgG4-RD) and other immune-mediated conditions CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology and inflammation, today announced the appointment of Debra Jeske Zack, M.D.
